[Hyperprolactinemia and prolactinomas. Results of surgical and drug therapy]. 1985

G Brabant, and I Brennecke, and H Herrmann, and H Friedrich, and T O Wagner, and A von zur Mühlen, and R D Hesch

185 patients with hyperprolactinaemia and prolactinoma were evaluated in a retrospective investigation. 128 patients were treated surgically whereby the prolactin serum level in 47% of the macroprolactinoma and 60% of the microprolactinoma patients was normalised (prolactin less than 25 ng/ml, no radiological evidence of tumor). Of those patients in whom the operation was less successful, a normal prolactin level could be achieved in 77% by additional therapy with dopamine agonists. Of 57 patients handled exclusively with drugs, the prolactin level was normalised by dopamine agonists in 78%. A small number of patients from both groups did not show a satisfactory fall in the prolactin level despite the use of markedly higher doses of dopamine agonists. During dopamine agonist therapy progressive tumor enlargement was detected radiologically in a previously operated patient.

UI MeSH Term Description Entries
D006966 Hyperprolactinemia Increased levels of PROLACTIN in the BLOOD, which may be associated with AMENORRHEA and GALACTORRHEA. Relatively common etiologies include PROLACTINOMA, medication effect, KIDNEY FAILURE, granulomatous diseases of the PITUITARY GLAND, and disorders which interfere with the hypothalamic inhibition of prolactin release. Ectopic (non-pituitary) production of prolactin may also occur. (From Joynt, Clinical Neurology, 1992, Ch36, pp77-8) Prolactin Hypersecretion Syndrome,Prolactin, Inappropriate Secretion,Hyperprolactinaemia,Inappropriate Prolactin Secretion,Inappropriate Prolactin Secretion Syndrome,Hyperprolactinemias,Hypersecretion Syndrome, Prolactin,Inappropriate Secretion Prolactin,Prolactin Secretion, Inappropriate,Secretion Prolactin, Inappropriate,Secretion, Inappropriate Prolactin,Syndrome, Prolactin Hypersecretion
D008090 Lisuride An ergot derivative that acts as an agonist at dopamine D2 receptors (DOPAMINE AGONISTS). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (SEROTONIN RECEPTOR AGONISTS). Lysuride Hydrogen Maleate,Methylergol Carbamide,Arolac,Cuvalit,Dopergin,Dopergine,Lisuride Hydrochloride,Lisuride Maleate,Lisuride Maleate (1:1),Lisuride Maleate, (8beta)-Isomer,Lisuride Mesylate,Lisuride Phosphate (1:1),Lisuride, (8alpha)-(+-)-Isomer,Lysenyl,Lysurid,Revanil,Carbamide, Methylergol,Hydrochloride, Lisuride,Hydrogen Maleate, Lysuride,Maleate, Lisuride,Mesylate, Lisuride
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009384 Paraneoplastic Endocrine Syndromes Syndromes resulting from inappropriate production of HORMONES or hormone-like materials by NEOPLASMS in non-endocrine tissues or not by the usual ENDOCRINE GLANDS. Such hormone outputs are called ectopic hormone (HORMONES, ECTOPIC) secretion. Ectopic Hormone Syndromes,Ectopic Hormone Syndrome,Endocrine Syndrome, Paraneoplastic,Paraneoplastic Endocrine Syndrome,Syndrome, Ectopic Hormone,Syndrome, Paraneoplastic Endocrine,Syndromes, Ectopic Hormone,Syndromes, Paraneoplastic Endocrine
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004873 Ergolines A series of structurally-related alkaloids that contain the ergoline backbone structure. Ergoline

Related Publications

G Brabant, and I Brennecke, and H Herrmann, and H Friedrich, and T O Wagner, and A von zur Mühlen, and R D Hesch
September 1980, Surgical neurology,
G Brabant, and I Brennecke, and H Herrmann, and H Friedrich, and T O Wagner, and A von zur Mühlen, and R D Hesch
March 2008, Endocrinology and metabolism clinics of North America,
G Brabant, and I Brennecke, and H Herrmann, and H Friedrich, and T O Wagner, and A von zur Mühlen, and R D Hesch
November 1991, Nederlands tijdschrift voor geneeskunde,
G Brabant, and I Brennecke, and H Herrmann, and H Friedrich, and T O Wagner, and A von zur Mühlen, and R D Hesch
August 1986, Obstetrics and gynecology,
G Brabant, and I Brennecke, and H Herrmann, and H Friedrich, and T O Wagner, and A von zur Mühlen, and R D Hesch
May 1985, Obstetrics and gynecology,
G Brabant, and I Brennecke, and H Herrmann, and H Friedrich, and T O Wagner, and A von zur Mühlen, and R D Hesch
January 1980, Rivista di neurologia,
G Brabant, and I Brennecke, and H Herrmann, and H Friedrich, and T O Wagner, and A von zur Mühlen, and R D Hesch
February 2024, Cancers,
G Brabant, and I Brennecke, and H Herrmann, and H Friedrich, and T O Wagner, and A von zur Mühlen, and R D Hesch
January 1978, Acta medica Austriaca,
G Brabant, and I Brennecke, and H Herrmann, and H Friedrich, and T O Wagner, and A von zur Mühlen, and R D Hesch
May 1983, Schweizerische medizinische Wochenschrift,
G Brabant, and I Brennecke, and H Herrmann, and H Friedrich, and T O Wagner, and A von zur Mühlen, and R D Hesch
January 1982, Annales de medecine interne,
Copied contents to your clipboard!